Merit Margin Growth, Cath-Lab Strength Aid Stock's Momentum In August
This article was originally published in The Gray Sheet
Executive Summary
Merit Medical stock continued to build momentum in August following the July release of strong second quarter financial results that reflect both improving business fundamentals like gross margins and competitive strength in its core cath-lab accessory market.
You may also be interested in...
J&J Reveling In RAVEL Drug-Coated Stent Data: No Restenosis At Six Months
Johnson and Johnson/Cordis' European RAVEL study data sets a high standard for other drug-coated stent developers, including no restenosis at six-month follow-up.
Novoste Parrying Drug-Coated Stents With Planned Indications For Beta-Cath
Novoste will rely on supplemental indications unaddressed by drug-coated stent developers to increase adoption of its Beta-Cath vascular brachytherapy system.
Zimmer
Bristol-Myers Squibb orthopedics spin-off commences independent public trading Aug. 7 on the New York Stock Exchange under the symbol "ZMH" (1"The Gray Sheet" July 30, 2001, p. 10)